United States · 
Who invested in Variant Bio?
Variant Bio's investors include General Catalyst, Lux Capital, SoftBank, SoftBank Vision Fund and Alexandria Venture Investments, and 1 more on record.
United States · Series B startup
Who invested in Variant Bio
Funding summaryUpdated 26 Oct 2026
$105Mraised across 1 round since 2021, from 1 source
- Latest round
- Series B, $105MNov 2021
- Investors
- 6
The rounds
- Nov 2021Series B$105M
Source recordedSEC filing: $95M sold, first sale Oct 2021
Founders and team
From Variant Bio's own website and the SEC filings it signed: 3 on the team.
- Andrew FarnumChief Executive Officer
- Holly VanceChief Operating Officer
- Stephane CastelExecutive Officer, Directori
On the board, as filediBob MoreElena VibochJosh WolfeJulie SunderlandStuart Nagae
Everyone who backed them
SoftBank Vision FundVC firm1round
Alexandria Venture InvestmentsVC firm1round
Missing a round, or an investor who was in one? Tell us.
Also claim to have backed them
This firm lists Variant Bio as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.
Quick answers about Variant Bio
How much has Variant Bio raised?
Variant Bio has raised $105M across 1 round since 2021.
When did Variant Bio last raise?
Variant Bio's most recent round was a Series B of $105M in Nov 2021.
What was Variant Bio's biggest round?
Its most recent round, $105M in Nov 2021, is also its largest on record.
Who backed Variant Bio first?
Variant Bio's first round on record, in Nov 2021, was backed by General Catalyst, Lux Capital and SoftBank and 3 others.
What stage is Variant Bio at?
Variant Bio's latest named round is a Series B, in Nov 2021.
Where is Variant Bio based?
Variant Bio is based in the United States.
Companies like Variant Bio
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.